Episode 33: Diana Sims-Silbermann, Clinician and Former Senior Trial Manager at Janssen Pharmaceuticals

Episode 33 September 20, 2023 00:26:33
Episode 33: Diana Sims-Silbermann, Clinician and Former Senior Trial Manager at Janssen Pharmaceuticals
Few & Far Between: How Biotech Gets Built
Episode 33: Diana Sims-Silbermann, Clinician and Former Senior Trial Manager at Janssen Pharmaceuticals

Sep 20 2023 | 00:26:33

/

Show Notes

View Full Transcript

Episode Transcript

"Having come from the clinical trial side, I then went to the management side. So, I understood all the problems that occur or arise when a clinical trial is being conducted - knowing what to watch out for, why the protocol is written the way it is. So that was an immense help." - Dr. Diana Sims-Silbermann Biorasi CEO, Chris O'Brien, welcomes Dr. Diana Sims-Silbermann to the latest episode of the Few & Far Between podcast. In her previous roles as a clinician and Senior Trial Manager for Janssen Pharmaceuticals, Dr. Sims-Silbermann has remained an inquisitive observer and skilled facilitator for clinical studies in Europe, with a keen understanding of regulatory requirements and patient centricity.

Other Episodes

Episode 14

November 10, 2021 00:46:16
Episode Cover

Episode 14: Bo Bigelow, Chairman at the Foundation for USP7-Related Diseases, and Trish Flanagan, President at the Yellow Brick Road Project

How will a rare disease diagnosis affect your family? Today's Few & Far Between episode features Bo Bigelow, Chairman at the Foundation for USP7-Related...

Listen

Episode 32

August 17, 2023 00:37:05
Episode Cover

Episode 32: Stephanie Wisner, Author, Co-Founder at Centivax

"In research or in biotech, time is expensive. Time is the most expensive thing that you have." - Stephanie Wisner, Author, Co-Founder at Centivax...

Listen

Episode 47

December 31, 2024 00:48:25
Episode Cover

Episode 47 - Marc Lajoie, CEO at Outpace Bio

"If you bring powerful technology to a problem that is well understood, then you can really make a difference." - Marc Lajoie, CEO at...

Listen